The FDA announced earlier today that ilunocitinib tablets (Zenrelia; Elanco) has received its approval. The latest drug from ...

A logical first approach might be to target appropriate members of the Janus kinase (JAK) family or the signal transducers and activators of transcription (STAT) family, as these proteins are ...

With more than 300 patients in the trial, dubbed FOREMOST, 33.9% of those assigned to apremilast achieved minimal disease ...

Tocilizumab -- an interleukin (IL)-6 receptor inhibitor -- was approved by the FDA in 2017 for the treatment of severe or ...

Of the kinase inhibitors in the drug development pipeline, the upstream Janus kinase (JAK) and spleen tyrosine kinase (Syk) targets are closer to the cell surface, and seem more promising targets ...

The atopic dermatitis (AD) market is projected to reach $16.7 billion by 2030, according to GlobalData. New therapies like ...

The JAK2 protein is particularly important for controlling blood cell production from hematopoietic (blood-forming) stem ...

The most frequently reported adverse events in children on a JAK inhibitor were blood and lymphatic system disorders, in a review of FDA and Canadian adverse event reports.

Aclaris Therapeutics has dosed the first subject in the Phase IIa clinical trial of ATI-2138 to treat moderate to severe ...

The strategy is large with over $7 billion in assets. Many holdings overlap with those in small-growth sibling Janus Henderson Venture JVTAX, which has nearly $3 billion in assets, and mid-growth ...

Barnard and Gibson’s experience running real estate strategies dates past their start on this fund as they’ve amassed an impressive record steering Janus Henderson Horizon Global Property ...